MHRA approves Pharma Mar’s lurbinectedin for extensive-stage small cell lung cancer
The treatment is for adults in combination with atezolizumab
Read More
Sep 25, 2026 | News, Regulatory
The treatment is for adults in combination with atezolizumab
Read MoreThe deal focuses on addressing critical unmet medical needs
Read MoreSep 23, 2026 | News, Regulatory
Trixeo is the first and only triple-combination therapy approved in the EU for patients 12 years and older, independent of exacerbation history
Read MoreSep 22, 2026 | News, Healthcare
The partnership introduces a world-first flu vaccine and extends the health security pandemic agreement
Read MoreThe Board will advise Galimedix on scientific and clinical strategy
Read MoreSep 21, 2026 | News, Regulatory
If approved, this would be the first IL-17A inhibitor licensed in Europe for adults with polymyalgia rheumatica
Read MoreAround 6,500 people are diagnosed with myeloma in the UK each year
Read MoreThe two companies aim to discover and develop novel bispecific antibodies for immunology and inflammation diseases
Read MoreSep 16, 2026 | News, Healthcare
The agreement will improve access to twice-yearly Lenacapavir across Latin America and the Caribbean
Read MoreSep 15, 2026 | News, Regulatory
Around 33,000 people in the UK are currently living with multiple myeloma, an incurable type of blood cancer
Read MoreThe results from a global phase 3 trial show the longest survival data ever reported in this setting
Read MoreSep 13, 2026 | News, Regulatory
The updated vaccine will be available to eligible groups as part of the 2026/27 NHS vaccination programme
Read More
